Status:
COMPLETED
Renal Effects of Melatonin Trial in Chronic Kidney Disease
Lead Sponsor:
University of Oklahoma
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This will be a prospective, double blinded, randomized, controlled pilot study to determine if there is any correlation between melatonin administration and proteinuria.
Detailed Description
Investigators plan to enroll up to 100 eligible participants in this pilot trial with 50 participants randomized to receive melatonin and 50 patients randomized to receive a placebo. Participants will...
Eligibility Criteria
Inclusion
- Are between ages 18 and up with chronic kidney disease (CKD) I-III (stage 3 kidney disease, kidney dysfunction)
- Random urine microalbumin of 30 mcg or greater (protein in the urine)
- Have ability to complete a sleep survey
- Currently not on melatonin therapy.
Exclusion
- End Stage Renal Disease
- CKD Stage IV (stage 4 with severe kidney dysfunction)
- Severe liver disease
- Chronic dialysis therapy
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2020
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04336566
Start Date
July 1 2019
End Date
May 13 2020
Last Update
August 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma School of Community Medicine
Tulsa, Oklahoma, United States, 74135